From Discovery To Development To Delivery

AZBio is committed to building a top-tier life science industry in Arizona.

Arizona’s bioscience industry has grown in recent years and by 2014 state bioscience firms employed just over 24,000 in nearly 1,300 business establishments. Four of the state’s five bioscience subsectors have contributed to its 2 percent overall employment gain since 2012, led by double-digit job growth in medical devices (up 11 percent). State academic institutions accounted for nearly $400 million in bioscience-related R&D expenditures in 2014 and NIH funding to these and other non-academic institutions totaled $150.6 million in 2015. Arizona inventors have had 1,751 patents issued in bioscience-related classes since 2012, primarily in medical and surgical devices but also in drugs and pharmaceuticals, microbiology and genetics, and in biochemistry. The state has seen a strong increase in venture capital invested in bioscience-related companies in recent years.  (Get The Facts)

AZBio Members Are Making LIFE Bettter

AZBio Members discover, develop, and deliver life-saving and life-changing innovations.

Premiere Supporters

Leadership Supporters

Sustaining Members

Get Connected With Arizona's Bioindustry

A key component in Arizona’s life science ecosystem, the Arizona Bioindustry Association (AZBio) is the only statewide organization exclusively focused on Arizona’s bioscience industry.  AZBio membership includes patient advocacy organizations, life science innovators, educators, healthcare partners and leading business organizations. AZBio is the statewide affiliate of the Biotechnology Innovation Organization (BIO) and works in partnership with AdvaMed, MDMA, and PhRMA to advance innovation and to ensure that the value delivered from life-changing and life-saving innovation benefits people in Arizona and around the world.

Success Stories – Good News from Arizona’s BioIndustry

Roche launches antibody test to aid in diagnosis of challenging prostate cancer cases

Tucson, AZ, April 12, 2017 Roche (SIX: RO, ROG; OTCQX:RHHBY) today announced the global launch of the anti-p504s (SP116) Rabbit Monoclonal Primary Antibody2 for prostate cancer diagnosis. This antibody has been validated for use in a dual stain with the VENTANA Basal Cell Cocktail (34ßE12+p63) to aid in distinguishing morphologically difficult cases as benign, atypical […]

HTG Molecular Diagnostics and Centre Léon Bérard Enter Into Molecular Profiling Research Agreement

HTG Molecular Diagnostics, Inc. (HTGM), a provider of instruments, reagents, and services for molecular profiling applications, announced that it has entered into a research agreement with Centre Léon Bérard, which provides the framework for molecular profiling studies aimed to advance precision medicine. The initial project utilizes the HTG EdgeSeq Oncology Biomarker Panel to retrospectively characterize immunologic […]

AZBio In The Loop

  Draft Legislation for User Fee Reauthorization Released on April 14, 2017 On April 14, 2017, the leaders of the Senate and House health committees  released a discussion draft of bipartisan legislation reauthorizing the Food and Drug Administration user fee agreements. HTG Molecular Diagnostics and Daiichi Sankyo Complete Master Services Agreement HTG Molecular Diagnostics has entered into a [...]

HTG Molecular Diagnostics and Daiichi Sankyo Complete Master Services Agreement

HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments, reagents and services for molecular profiling applications, announced that it has entered into a master services agreement with Daiichi Sankyo Company, Limited (Daiichi Sankyo) for work to be performed in HTG’s VERI/O laboratory. The initial project includes the development of a custom assay for the detection […]

AZBio Builds Relationships With Partners Across The Country

Partner Opportunities for AZBio Members

  • AZBio Members Save $100 Off Registration - Click here to learn more